OII 250117 40.00P (OII250117P40000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

OII250117P40000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 24 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Down -15.86% in 4 Weeks, Here's Why You Should You Buy the Dip in Oceaneering International (OII)
Yahoo FinanceDec 20 09:35 ET
Express News | Oceaneering Appoints William Merz to Succeed Philip Beierl as Senior Vice President, Aerospace and Defense Technologies
ReutersDec 19 17:01 ET
Barclays Maintains Oceaneering International(OII.US) With Hold Rating, Maintains Target Price $26
Moomoo NewsDec 19 06:31 ET · Ratings
Barclays Upgrades Oceaneering International(OII.US) to Hold Rating, Raises Target Price to $26
Moomoo NewsDec 19 04:33 ET · Ratings
Oceaneering International Analyst Ratings
BenzingaDec 18 06:57 ET · Ratings
Express News | Oceaneering International Inc : Barclays Raises Target Price to $26 From $22
ReutersDec 18 04:47 ET

Comments

Moomoo AI

Feb 29 07:55

The modest level of insider ownership and lack of insider transactions in the last three months suggest alignment with shareholder interests. However, significant insider selling over the past year could be a red flag for investors.

Insiders At Oceaneering International Sold US$2.5m In Stock, Alluding To Potential Weakness

Moomoo AI

Jan 29 05:53

Oceaneering International, Inc.'s transition from loss to profitability justifies its strong share price gain. Despite slowing gains, the company's future financial health remains crucial for shareholders.

Oceaneering International (NYSE:OII) Delivers Shareholders Impressive 37% CAGR Over 3 Years, Surging 6.4% in the Last Week Alone

Moomoo AI

Jan 11 07:09

Oceaneering International's respectable ROE is overshadowed by its high debt level. Investors should consider the company's performance potential in less favorable credit markets. High ROE without debt typically indicates a high-quality business.

Did Oceaneering International, Inc. (NYSE:OII) Use Debt To Deliver Its ROE Of 13%?

Moomoo Breakfast US

Jun 10, 2022 07:20

Columns Today's pre-market stock movers: DOCU, BGNE, RBLX, SFIX and more

Gainers:
• $Cogent Biosciences (COGT.US)$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions (UNVR.US)$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts (MTN.US)$ +6% (In reaction to earnings/guidance)
• $BeiGene (BGNE.US)$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...